Patents by Inventor Mika Fujinuma

Mika Fujinuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDINE DERIVATIVE
    Publication number: 20170190694
    Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 6, 2017
    Applicant: Teijin Pharma Limited
    Inventors: Akinobu MARUYAMA, Hirofumi KAMADA, Mika FUJINUMA, Susumu TAKEUCHI, Hiroshi SAITOH, Yoshimasa TAKAHASHI
  • Pyridine derivative
    Patent number: 9637469
    Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: May 2, 2017
    Assignee: Teijin Pharma Limited
    Inventors: Akinobu Maruyama, Hirofumi Kamada, Mika Fujinuma, Susumu Takeuchi, Hiroshi Saitoh, Yoshimasa Takahashi
  • PYRIDINE DERIVATIVE
    Publication number: 20150284358
    Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
    Type: Application
    Filed: November 13, 2013
    Publication date: October 8, 2015
    Applicant: Teijin Pharma Limited
    Inventors: Akinobu Maruyama, Hirofumi Kamada, Mika Fujinuma, Susumu Takeuchi, Hiroshi Saitoh, Yoshimasa Takahashi